Header Logo

Connection

Anne-Marie Malfait to Humans

This is a "connection" page, showing publications Anne-Marie Malfait has written about Humans.
Connection Strength

1.133
  1. Doubling down on osteoarthritis: statement from the incoming editors-in-chief. Osteoarthritis Cartilage. 2022 08; 30(8):1013-1014.
    View in: PubMed
    Score: 0.046
  2. The Genesis of Pain in Osteoarthritis: Inflammation as a Mediator of Osteoarthritis Pain. Clin Geriatr Med. 2022 05; 38(2):221-238.
    View in: PubMed
    Score: 0.046
  3. Can we prevent chronic osteoarthritis pain? A view from the bench. Osteoarthritis Cartilage. 2021 12; 29(12):1635-1637.
    View in: PubMed
    Score: 0.044
  4. Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives. Rheum Dis Clin North Am. 2021 05; 47(2):165-180.
    View in: PubMed
    Score: 0.043
  5. Targeting neurotrophic factors: Novel approaches to musculoskeletal pain. Pharmacol Ther. 2020 07; 211:107553.
    View in: PubMed
    Score: 0.040
  6. Why we should study osteoarthritis pain in experimental models in both sexes. Osteoarthritis Cartilage. 2020 04; 28(4):397-399.
    View in: PubMed
    Score: 0.039
  7. The "elusive DMOAD": Aggrecanase inhibition from laboratory to clinic. Clin Exp Rheumatol. 2019 Sep-Oct; 37 Suppl 120(5):130-134.
    View in: PubMed
    Score: 0.038
  8. An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis. Semin Immunopathol. 2019 09; 41(5):583-594.
    View in: PubMed
    Score: 0.038
  9. New concepts in osteoarthritis. Clin Exp Rheumatol. 2019 Sep-Oct; 37 Suppl 120(5):2.
    View in: PubMed
    Score: 0.038
  10. What is new in pain modification in osteoarthritis? Rheumatology (Oxford). 2018 05 01; 57(suppl_4):iv99-iv107.
    View in: PubMed
    Score: 0.035
  11. Osteoarthritis pain: What are we learning from animal models? Best Pract Res Clin Rheumatol. 2017 10; 31(5):676-687.
    View in: PubMed
    Score: 0.035
  12. Peripheral Mechanisms Contributing to Osteoarthritis Pain. Curr Rheumatol Rep. 2018 02 26; 20(2):9.
    View in: PubMed
    Score: 0.034
  13. Why we should study pain in animal models of rheumatic diseases. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):37-39.
    View in: PubMed
    Score: 0.033
  14. Time to be positive about negative data? Osteoarthritis Cartilage. 2017 03; 25(3):351-353.
    View in: PubMed
    Score: 0.032
  15. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr Opin Rheumatol. 2017 01; 29(1):110-118.
    View in: PubMed
    Score: 0.032
  16. Emerging Targets for the Management of Osteoarthritis Pain. Curr Osteoporos Rep. 2016 12; 14(6):260-268.
    View in: PubMed
    Score: 0.031
  17. Osteoarthritis year in review 2015: biology. Osteoarthritis Cartilage. 2016 Jan; 24(1):21-6.
    View in: PubMed
    Score: 0.029
  18. The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain. Curr Osteoporos Rep. 2015 Oct; 13(5):318-26.
    View in: PubMed
    Score: 0.029
  19. On the predictive utility of animal models of osteoarthritis. Arthritis Res Ther. 2015 Sep 14; 17:225.
    View in: PubMed
    Score: 0.029
  20. Osteoarthritis joint pain: the cytokine connection. Cytokine. 2014 Dec; 70(2):185-93.
    View in: PubMed
    Score: 0.027
  21. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 2013 Nov; 9(11):654-64.
    View in: PubMed
    Score: 0.025
  22. Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets. Curr Rheumatol Rep. 2013 Aug; 15(8):350.
    View in: PubMed
    Score: 0.025
  23. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A. 2012 Dec 11; 109(50):20602-7.
    View in: PubMed
    Score: 0.024
  24. A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Ann Rheum Dis. 2012 Jun; 71(6):1042-8.
    View in: PubMed
    Score: 0.023
  25. A review of the ADAMTS family, pharmaceutical targets of the future. Curr Pharm Des. 2009; 15(20):2359-74.
    View in: PubMed
    Score: 0.018
  26. Proprotein convertase activation of aggrecanases in cartilage in situ. Arch Biochem Biophys. 2008 Oct 01; 478(1):43-51.
    View in: PubMed
    Score: 0.018
  27. Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. Curr Pharm Biotechnol. 2008 Feb; 9(1):16-23.
    View in: PubMed
    Score: 0.017
  28. ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms. Arch Biochem Biophys. 2005 Dec 01; 444(1):34-44.
    View in: PubMed
    Score: 0.015
  29. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J Biol Chem. 2004 Apr 23; 279(17):17554-61.
    View in: PubMed
    Score: 0.013
  30. The usual suspects: verdict not guilty? Arthritis Rheum. 2003 Dec; 48(12):3304-7.
    View in: PubMed
    Score: 0.013
  31. Age-Associated Changes in Knee Osteoarthritis, Pain-Related Behaviors, and Dorsal Root Ganglia Immunophenotyping of Male and Female Mice. Arthritis Rheumatol. 2023 10; 75(10):1770-1780.
    View in: PubMed
    Score: 0.012
  32. Sensory Profiling in Classical Ehlers-Danlos Syndrome: A Case-Control Study Revealing Pain Characteristics, Somatosensory Changes, and Impaired Pain Modulation. J Pain. 2023 11; 24(11):2063-2078.
    View in: PubMed
    Score: 0.012
  33. Piezo2 expressing nociceptors mediate mechanical sensitization in experimental osteoarthritis. Nat Commun. 2023 04 29; 14(1):2479.
    View in: PubMed
    Score: 0.012
  34. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem. 2002 Jun 21; 277(25):22201-8.
    View in: PubMed
    Score: 0.011
  35. Mitochondrial calcium uniporter deletion prevents painful diabetic neuropathy by restoring mitochondrial morphology and dynamics. Pain. 2022 03 01; 163(3):560-578.
    View in: PubMed
    Score: 0.011
  36. Pain in the Ehlers-Danlos syndromes: Mechanisms, models, and challenges. Am J Med Genet C Semin Med Genet. 2021 12; 187(4):429-445.
    View in: PubMed
    Score: 0.011
  37. The innate immune response as a mediator of osteoarthritis pain. Osteoarthritis Cartilage. 2020 05; 28(5):562-571.
    View in: PubMed
    Score: 0.010
  38. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019 10; 160(10):2210-2220.
    View in: PubMed
    Score: 0.010
  39. Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later. Arthritis Rheumatol. 2019 08; 71(8):1276-1284.
    View in: PubMed
    Score: 0.009
  40. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):85-87.
    View in: PubMed
    Score: 0.008
  41. Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. J Orthop Res. 2018 03; 36(3):864-875.
    View in: PubMed
    Score: 0.008
  42. PCSK6-mediated corin activation is essential for normal blood pressure. Nat Med. 2015 Sep; 21(9):1048-53.
    View in: PubMed
    Score: 0.007
  43. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 2015 Aug; 23(8):1254-66.
    View in: PubMed
    Score: 0.007
  44. Coculture of human articular chondrocytes with peripheral blood mononuclear cells as a model to study cytokine-mediated interactions between inflammatory cells and target cells in the rheumatoid joint. In Vitro Cell Dev Biol Anim. 1994 Nov; 30A(11):747-52.
    View in: PubMed
    Score: 0.007
  45. Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose. J Rheumatol. 1994 Feb; 21(2):314-20.
    View in: PubMed
    Score: 0.006
  46. Second conference on spondylarthropathies and the gut. Clin Exp Rheumatol. 1994 Jan-Feb; 12(1):111-6.
    View in: PubMed
    Score: 0.006
  47. Nanoparticles for improved local retention after intra-articular injection into the knee joint. Pharm Res. 2013 Jan; 30(1):257-68.
    View in: PubMed
    Score: 0.006
  48. Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to toll-like receptor 4 and toll-like receptor 2 ligands via soluble CD14. Arthritis Rheum. 2012 Jul; 64(7):2268-77.
    View in: PubMed
    Score: 0.006
  49. Structure analysis reveals the flexibility of the ADAMTS-5 active site. Protein Sci. 2011 Apr; 20(4):735-44.
    View in: PubMed
    Score: 0.005
  50. An immunoaffinity liquid chromatography-tandem mass spectrometry assay for detection of endogenous aggrecan fragments in biological fluids: Use as a biomarker for aggrecanase activity and cartilage degradation. Anal Biochem. 2010 Nov 15; 406(2):113-23.
    View in: PubMed
    Score: 0.005
  51. ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271). Arthritis Rheum. 2009 Sep; 60(9):2704-13.
    View in: PubMed
    Score: 0.005
  52. Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors. J Biol Chem. 2009 Sep 04; 284(36):24185-91.
    View in: PubMed
    Score: 0.005
  53. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J Biol Chem. 2008 Jan 18; 283(3):1501-1507.
    View in: PubMed
    Score: 0.004
  54. Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing. Antimicrob Agents Chemother. 2007 Oct; 51(10):3554-61.
    View in: PubMed
    Score: 0.004
  55. Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (Aggrecanase 1). Biochemistry. 2007 May 29; 46(21):6393-401.
    View in: PubMed
    Score: 0.004
  56. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum. 2007 Feb; 56(2):575-85.
    View in: PubMed
    Score: 0.004
  57. Identification of fibronectin neoepitopes present in human osteoarthritic cartilage. Arthritis Rheum. 2006 Sep; 54(9):2912-22.
    View in: PubMed
    Score: 0.004
  58. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. J Biol Chem. 2004 Apr 09; 279(15):15434-40.
    View in: PubMed
    Score: 0.003
  59. Future prospects for anti-cytokine treatment. Ann Rheum Dis. 2000 Nov; 59 Suppl 1:i119-22.
    View in: PubMed
    Score: 0.003
  60. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol. 1997 Sep 15; 159(6):2867-76.
    View in: PubMed
    Score: 0.002
  61. Standardization of nutrient media for isolated human articular chondrocytes in gelified agarose suspension culture. Osteoarthritis Cartilage. 1995 Dec; 3(4):249-59.
    View in: PubMed
    Score: 0.002
  62. Aspergilloma of the thoracic wall. Another cold spot lesion on bone scanning. Clin Nucl Med. 1995 May; 20(5):462.
    View in: PubMed
    Score: 0.002
  63. T cell receptor V beta usage in rheumatoid nodules: marked oligoclonality among IL-2 expanded lymphocytes. Clin Immunol Immunopathol. 1993 Jul; 68(1):29-34.
    View in: PubMed
    Score: 0.002
  64. Influence of interferon-gamma on isolated chondrocytes from human articular cartilage. Dose dependent inhibition of cell proliferation and proteoglycan synthesis. J Rheumatol. 1993 Jun; 20(6):1020-6.
    View in: PubMed
    Score: 0.002
  65. Size distribution of native aggrecan aggregates of human articular chondrocytes in agarose. In Vitro Cell Dev Biol Anim. 1993 May; 29A(5):356-8.
    View in: PubMed
    Score: 0.002
  66. Development of immortalized human articular cartilage cell lines. Agents Actions Suppl. 1993; 39:267-72.
    View in: PubMed
    Score: 0.001
  67. T-cell receptor expression in patients with rheumatic diseases. Prog Histochem Cytochem. 1992; 26(1-4):218-22.
    View in: PubMed
    Score: 0.001
  68. Influence of human recombinant interleukin-1 beta on human articular cartilage. Mitotic activity and proteoglycan metabolism. Clin Exp Rheumatol. 1991 Sep-Oct; 9(5):481-8.
    View in: PubMed
    Score: 0.001
  69. The synthesis and immobilisation of cartilage-specific proteoglycan by human chondrocytes in different concentrations of agarose. Clin Exp Rheumatol. 1990 Jul-Aug; 8(4):371-8.
    View in: PubMed
    Score: 0.001
  70. Proteoglycan metabolism in isolated chondrocytes from human cartilage. Influence of niflumic acid. Clin Rheumatol. 1990 Mar; 9(1):32-41.
    View in: PubMed
    Score: 0.001
  71. Proteoglycan metabolism in tissue-cultured human articular cartilage. Influence of niflumic acid. Scand J Rheumatol. 1990; 19(4):257-68.
    View in: PubMed
    Score: 0.001
  72. Proteoglycan metabolism in tissue cultured human articular cartilage. Influence of piroxicam. J Rheumatol. 1989 Mar; 16(3):355-62.
    View in: PubMed
    Score: 0.001
  73. Proteoglycan metabolism in isolated chondrocytes from human cartilage and in short-term tissue-cultured human articular cartilage. Clin Exp Rheumatol. 1989 Jan-Feb; 7(1):13-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.